secwatch.observer — SEC 8-K summary
======================================

Issuer:     LivaNova PLC (LIVN)
CIK:        0001639691
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001639691-23-000108
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LivaNova Q3 revenue $286M (+13.3% YoY); raises full-year guidance
-----------------------------------------------------------------

- Revenue $286.1M, up 13.3% reported and 12.1% constant currency vs prior year.
- GAAP diluted loss per share $0.14; adjusted diluted EPS $0.73.
- Received FDA 510(k) clearance and CE Mark for Essenz In-Line Blood Monitor.
- Raised full-year 2023 revenue and adjusted diluted EPS guidance.
- Double-digit revenue growth across all regions and three business units.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1639691/000163969123000108/0001639691-23-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1639691/000163969123000108/livn-20231101.htm
  HTML page:      https://secwatch.observer/filing/0001639691-23-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer